PALO ALTO, Calif. , Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024 . "In the third quarter we hosted an Investor R&D Day in New York ," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of... Read More

PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies... Read More

PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024 , in Chicago, Illinois . Presentation and Panel details are below:... Read More

NEW YORK , Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York . The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually by clicking here . A link to the live webcast, replay and presentation slides of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/ . A replay... Read More

PALO ALTO, Calif. , Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024 , in New York City from 10:30 am ET to 12:30... Read More

PALO ALTO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024 . "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy... Read More

PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024 , 8:00 AM ET ( 5:00 AM PT ), New York, New... Read More

PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth , M.D., Chief Executive Officer of Kodiak Sciences.... Read More

PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the... Read More

Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101. Novel small molecules... Read More

Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024 New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab... Read More

PALO ALTO, Calif. , March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024 . Management will host a conference call and live webcast to discuss... Read More

PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second... Read More

PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 , at 7:30 a.m. Pacific Time ( 10:30... Read More

PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6 th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023 , at 3:25 p.m. Eastern Time ( 12:25... Read More

PALO ALTO, Calif. , Nov. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023 . "We have three retinal disease prospects in our pipeline: two molecules built with our antibody biopolymer conjugate platform (ABC Platform), (1) tarcocimab ABC, an anti-VEGF bioconjugate, (2) KSI-501 ABC, a bispecific anti-IL-6 and anti-VEGF... Read More

Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients, tarcocimab and the ABC platform continue to demonstrate differentiated durability. Following dialogue with US regulatory authorities, Kodiak plans to conduct one additional pivotal study with a commercial formulation of tarcocimab. New regulatory strategy could support a single Biologics... Read More

PALO ALTO, Calif. , Nov. 1, 2023 /PRNewswire/ -- Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology (AAO) to be held November 3-6 in San Francisco . During the Retina Subspecialty Day on November 3 , detailed results will be presented for the first time from the Phase 3 GLOW study of tarcocimab tedromer in... Read More

PALO ALTO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet... Read More

PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023 , at 12:55 p.m. Eastern Time... Read More

Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over one-year After 4 initiating doses in the first 6 months, approximately half of tarcocimab-treated patients required no additional injections in the second 6 months Low and comparable rates of cataract adverse events were observed (tarcocimab 4.9% vs aflibercept 2.8%) These... Read More

PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2023 . "We experienced a significant setback with the recently announced topline data for our... Read More

PALO ALTO, Calif. , July 24, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate. The DAYLIGHT study was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high intensity dosing regimen of tarcocimab tedromer in 557 treatment-naïve subjects with wet... Read More

PALO ALTO, Calif. , May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 7, 2023 , 1:30 PM ET ( 10:30 AM PT ), New York, New York... Read More

PALO ALTO, Calif. , May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023 . "We are on the cusp of four Phase 3 study readouts in major indications, starting with... Read More

PALO ALTO, Calif. , April 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc . (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that multiple scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO)... Read More

PALO ALTO, Calif. , April 3, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501... Read More

PALO ALTO, Calif. , March 28, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022 . "We are running a comprehensive development program for tarcocimab tedromer... Read More

PALO ALTO, Calif. , Feb. 9, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that a presentation will be made at the upcoming Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting including clinical data from Kodiak's investigational... Read More

PALO ALTO, Calif. , Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 , at 9:00 a.m. Pacific Time ( 12:00... Read More